Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.

Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA

American journal of physiology. Gastrointestinal and liver physiology1 Jun 2000Cited by 94 (Europe PMC)

PMID10859225DOI10.1152/ajpgi.2000.278.6.g946PepBankPUB-10859225

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialMechanism
In healthy humans, pramlintide at 30 microg prolonged gastric emptying half-time to 169 minutes versus 112 minutes with placebo.
In plain wordsIn healthy humans, low-dose pramlintide delayed stomach emptying compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGastric emptying half-time, low dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30 microg tid · subcutaneousAs given in this study (human).
Measurements
Gastric emptying half-time
169 min
30 microg pramlintide tid, SE 12 min
Gastric emptying half-time
112 min
placebo, SE 8.7 min
Source sentences
Summary
Pramlintide delayed gastric emptying [half-time (t(1/2)): 112 min (SE 8.7 min), 169 min (SE 12 min), or 177 min (SE 25 min) after placebo or 30- or 60-microg pramlintide treatment, respectively; P = 0.033].
2 context sentences(design, population, supporting numbers)
Summary · context
Pramlintide at 30 and 60 microg delays gastric emptying in healthy humans
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
Report a problemFND-1085922501
02HumanRandomized controlled trialMechanism
In healthy humans, pramlintide at 60 microg prolonged gastric emptying half-time to 177 minutes versus 112 minutes with placebo.
In plain wordsIn healthy humans, high-dose pramlintide delayed stomach emptying compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGastric emptying half-time, high dose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
60 microg tid · subcutaneousAs given in this study (human).
Measurements
Gastric emptying half-time
177 min
60 microg pramlintide tid, SE 25 min
Gastric emptying half-time
112 min
placebo, SE 8.7 min
Source sentences
Summary
Pramlintide delayed gastric emptying [half-time (t(1/2)): 112 min (SE 8.7 min), 169 min (SE 12 min), or 177 min (SE 25 min) after placebo or 30- or 60-microg pramlintide treatment, respectively; P = 0.033].
2 context sentences(design, population, supporting numbers)
Summary · context
Pramlintide at 30 and 60 microg delays gastric emptying in healthy humans
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
Report a problemFND-1085922502
03HumanRandomized controlled trialMechanism
In humans, pramlintide did not significantly affect small bowel transit compared with placebo.
In plain wordsIn humans, pramlintide did not significantly change small bowel transit compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSmall bowel transit
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30 or 60 microg tid · subcutaneousAs given in this study (human).
Source sentences
Summary
Pramlintide did not significantly affect small bowel or colonic transit.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
Report a problemFND-1085922503
04HumanRandomized controlled trialMechanism
In humans, pramlintide did not significantly affect colonic transit compared with placebo.
In plain wordsIn humans, pramlintide did not significantly change colon transit compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeColonic transit
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30 or 60 microg tid · subcutaneousAs given in this study (human).
Source sentences
Summary
Pramlintide did not significantly affect small bowel or colonic transit.
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
Report a problemFND-1085922504
05HumanRandomized controlled trialMechanism
In humans, pramlintide lowered pancreatic polypeptide concentrations in the first postprandial hour compared with placebo.
In plain wordsIn humans, pramlintide lowered pancreatic polypeptide during the first hour after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePancreatic polypeptide concentration
Study
n: not reported in source
Comparator
Placebo
Outcome group
Endogenous peptide levels · Gastrointestinal
Studied dose
30 or 60 microg tid · subcutaneousAs given in this study (human).
Source sentences
Summary
Pancreatic polypeptide concentrations in the first postprandial hour were lower with pramlintide than with placebo (P<0.01 for drug effect).
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
Report a problemFND-1085922505

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

06HumanNot a test of Pramlintide (Symlin) aloneOther designMechanism
In a human pramlintide dose-response study, mean pancreatic polypeptide in the first postprandial hour correlated with gastric emptying half-time; the source calls it inverse but reports R(s) = 0.48 (P = 0.044).
In plain wordsIn the human pramlintide study, pancreatic polypeptide and stomach emptying time were linked. The source calls it inverse but gives a positive coefficient.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedPancreatic polypeptide and gastric emptying correlation
Study
n: not reported in source
Outcome group
Gastrointestinal motility · Gastrointestinal
Measurements
Spearman correlation coefficient
0.48 R(s)
mean pancreatic polypeptide in first postprandial hour versus gastric emptying half-time
Source sentences
Summary
An inverse correlation was observed between mean pancreatic polypeptide concentrations in the first postprandial hour and gastric emptying t(1/2) [Spearman correlation coefficient (R(s)) = 0.48; P = 0.044].
1 context sentence(design, population, supporting numbers)
Summary · context
We investigated the effects of pramlintide on gastrointestinal and colonic transit and on the plasma pancreatic polypeptide response to the meal in a parallel-group dose-response study with subjects randomized to placebo, or 30 or 60 microg (tid, sc) of pramlintide.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1085922506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.